rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Ron Squarer

Director

Company insider

Files Form 4 as: Director, Nuvalent; Director, ADC Therapeutics SA; Director, Travere Therapeutics; Director, Deciphera Pharmaceuticals; CEO, Array Biopharma; Chief Commercial Officer, Hospira.

Every Form 4 they filed

In numbers

Trades disclosed
155
Buys
1
Sells
10
Bought
$74K
Sold
$20.7M
Companies
6
Companies where not an officer
4
First trade
25 Feb 2009
Last trade
15 Jul 2026
Last filed
15 Jul 2026

Companies traded

Where they are an officer
Array BiopharmaDirector, Officer · last 30 Jul 20190 buys · 7 sells
HospiraOfficer · last 24 Feb 20111 buy · 2 sells
Everywhere else they filed: board seats, 10% stakes, other companies
NuvalentDirector · Biotechnology · last 15 Jul 20260 buys · 0 sells
ADCT ADC Therapeutics SADirector · Biotechnology · last 3 Jun 20260 buys · 1 sell
TVTX Travere TherapeuticsDirector · Biotechnology · last 19 May 20260 buys · 0 sells
Deciphera PharmaceuticalsDirector · last 11 Jun 20240 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
15 Jul 2026filed 15 Jul 2026NuvalentBiotechnologySEC FORM 4 Code D—6,281filing
15 Jul 2026filed 15 Jul 2026Nuvalentoption or derivative · BiotechnologySEC FORM 4 Code D—4,418filing
15 Jul 2026filed 15 Jul 2026Nuvalentoption or derivativeSEC FORM 4 Code D—4,418filing
15 Jul 2026filed 15 Jul 2026NuvalentSEC FORM 4 Code D—6,281filing
16 Jun 2026filed 18 Jun 2026NuvalentBiotechnologySEC FORM 4 Code A—3,444 at $0.00filing
16 Jun 2026filed 18 Jun 2026NuvalentSEC FORM 4 Code A—3,444 at $0.00filing
3 Jun 2026filed 3 Jun 2026ADCT ADC Therapeutics SABiotechnologySEC FORM 4 Code F$47K15,196 at $3.08filing
3 Jun 2026filed 3 Jun 2026ADCT ADC Therapeutics SABiotechnologySEC FORM 4 Code F$47K15,196 at $3.08filing
1 Jun 2026filed 3 Jun 2026ADCT ADC Therapeutics SABiotechnologySEC FORM 4 Code A—45,000 at $0.00filing
1 Jun 2026filed 3 Jun 2026ADCT ADC Therapeutics SABiotechnologySEC FORM 4 Code A—45,000 at $0.00filing
19 May 2026filed 21 May 2026TVTX Travere TherapeuticsBiotechnologySEC FORM 4 Code A—4,000 at $0.00filing
19 May 2026filed 21 May 2026TVTX Travere Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—12,000 at $0.00filing
19 May 2026filed 21 May 2026TVTX Travere Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—12,000 at $0.00filing
19 May 2026filed 21 May 2026TVTX Travere TherapeuticsBiotechnologySEC FORM 4 Code A—4,000 at $0.00filing
10 Dec 2025filed 11 Dec 2025Nuvalentoption or derivativeSEC FORM 4 Code A—4,418 at $0.00filing
10 Dec 2025filed 11 Dec 2025NuvalentSEC FORM 4 Code A—2,837 at $0.00filing
13 Jun 2025filed 17 Jun 2025ADCT ADC Therapeutics SABiotechnologySEC FORM 4 Code F$54K15,184 at $3.58filing
3 Jun 2025filed 5 Jun 2025ADCT ADC Therapeutics SABiotechnologySEC FORM 4 Code A—40,000 at $0.00filing
15 May 2025filed 16 May 2025TVTX Travere Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—19,500 at $0.00filing
15 May 2025filed 16 May 2025TVTX Travere TherapeuticsBiotechnologySEC FORM 4 Code A—6,500 at $0.00filing

News

Head to Head Survey: Kymera Therapeutics (NASDAQ:KYMR) versus ADC Therapeutics (NYSE:ADCT)ADCT · dailypolitical.com · 8 Oct 2026

0 headlines in the last 90 days name Ron Squarer; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.

Sectors

Health Care1
Not placed10

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.